Key Figures Q4 2020

SEK m, unless otherwise stated

2020

Oct-Dec

2019

Oct-Dec

2020

Jan-Dec

2019

Jan-Dec

2019-2020

Oct-Dec Δ

Net revenues

159.2

238.1

663.6

844.8

-33%

Cost of goods sold

-11.3

-23.0

-65.6

-105.6

-51%

Operating expenses

-158.9

-143.5

-617.9

-508.8

11%

EBIT

-11.0

71.5

-19.9

231.2

-115%

EBIT margin, %

-6.9

30.0

-3.0

27.4

-36.9 ppt

EBITDA

1.0

85.8

19.0

272.1

-99%

Earnings per share, before dilution, SEK

-1.45

1.12

-2.45

6.33

-230%

Earnings per share, after dilution, SEK

-1.45

1.10

-2.45

6.20

-232%

Cash flow from operating activities

-11.2

60.2

16.8

287.0

-119%

Cash and cash equivalents

505.3

816.8

505.3

816.8

-38%

Net revenues and EBIT per segment Q4 2020

SEK m

                               Revenues

                                   EBIT

 

2020

Oct-Dec

2019

Oct-Dec

2020

Jan-Dec

2019

Jan-Dec

2020

Oct-Dec

2019

Oct-Dec

2020

Jan-Dec

2019

Jan-Dec

ZUBSOLV® US

143.1

190.5

623.3

719.2

-

-

-

-

US Pharma – total

143.1

190.5

623.3

719.2

94.4

95.5

331.2

347.1

Digital Therapeutics (DTx) product sales

0.0

-

0.0

-

-

-

-

-

Digital Therapeutics (DTx) – total

0.0

-

0.0

-

-65.3

0.9

-175.4

-0.9

Abstral® royalties

15.1

46.2

29.7

112.6

-

-

-

-

Edluar® royalties

0.9

1.3

10.4

11.6

-

-

-

-

ZUBSOLV® - ex US

-

-

0.1

0.1

-

-

-

-

OX-MPI

-

0.0

-

1.4

-

-

-

-

HQ & Pipeline

segment – total

16.0

47.5

40.2

125.6

-40.1

-23.2

-175.8

-115.0

Total

159.2

238.1

663.6

844.8

-11.0

71.5

-19.9

231.2


Cash flow Q4 2020

 

SEK m

2020

Oct-Dec

2019

Oct-Dec

2020

Jan-Dec

2019

Jan-Dec

Cash flow from operating activities

-11.2

60.2

16.8

287.0

Investment activities

-29.0

-11.0

-189.2

-22.4

Financing activities

-4.3

-4.3

-111.3

-53.7

Cash flow (excl exchange rate differences)

-44.6

44.8

-283.7

210.8

Liquid funds

505.3

816.8

505.3

816.8